Abstract
Ductal adenocarcinoma of the pancreas is one of the highly aggressive tumors; the overall survival rate of less than 6% is probably due to biological rapid development and late tumor stage at the time of diagnosis [1]. Recently a progression model suggested that infiltrating pancreatic cancer arises from pancreatic duct lesions that shows to harbour activating KRAS point mutation [2]. Since 1988 KRAS is the most significant genetic alteration in pancreatic cancer and is considered as an early event in tumor progression [3]. In the present study we investigated a selected population of patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, with disease free resection margins, in order to evaluate whether a specific mutation could be related to a worst median survival time or onset of tumor recurrence and metastatisation.
Highlights
IntroductionDuctal adenocarcinoma of the pancreas is one of the highly aggressive tumors; the overall survival rate of less than 6% is probably due to biological rapid development and late tumor stage at the time of diagnosis [1].Recently a progression model suggested that infiltrating pancreatic cancer arises from pancreatic duct lesions that shows to harbour activating KRAS point mutation [2].Since 1988 KRAS is the most significant genetic alteration in pancreatic cancer and is considered as an early event in tumor progression [3].In the present study we investigated a selected population of patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, with disease free resection margins, in order to evaluate whether a specific mutation could be related to a worst median survival time or onset of tumor recurrence and metastatisation
In the present study we investigated a selected population of patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, with disease free resection margins, in order to evaluate whether a specific mutation could be related to a worst median survival time or onset of tumor recurrence and metastatisation
(7.41%) develop both local recurrence and liver metastases; brain metastases was observed in 1 case (3.70%) and peritoneal carcinomatosis in 1 case (3.70%)
Summary
Ductal adenocarcinoma of the pancreas is one of the highly aggressive tumors; the overall survival rate of less than 6% is probably due to biological rapid development and late tumor stage at the time of diagnosis [1].Recently a progression model suggested that infiltrating pancreatic cancer arises from pancreatic duct lesions that shows to harbour activating KRAS point mutation [2].Since 1988 KRAS is the most significant genetic alteration in pancreatic cancer and is considered as an early event in tumor progression [3].In the present study we investigated a selected population of patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, with disease free resection margins, in order to evaluate whether a specific mutation could be related to a worst median survival time or onset of tumor recurrence and metastatisation. Ductal adenocarcinoma of the pancreas is one of the highly aggressive tumors; the overall survival rate of less than 6% is probably due to biological rapid development and late tumor stage at the time of diagnosis [1]. A progression model suggested that infiltrating pancreatic cancer arises from pancreatic duct lesions that shows to harbour activating KRAS point mutation [2]. Since 1988 KRAS is the most significant genetic alteration in pancreatic cancer and is considered as an early event in tumor progression [3]. In the present study we investigated a selected population of patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma, with disease free resection margins, in order to evaluate whether a specific mutation could be related to a worst median survival time or onset of tumor recurrence and metastatisation
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
